Parkinson's disease diffusion MRI is not affected by acute antiparkinsonian medication

Jae Woo Chung, Roxana G. Burciu, Edward Ofori, Priyank Shukla, Michael S. Okun, Christopher W. Hess, David E. Vaillancourt

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective A prior longitudinal study demonstrates that free-water diffusion magnetic resonance imaging (dMRI) tracks progression in the substantia nigra (Ofori et al., 2015b). Here, we test the acute effects of antiparkinsonian medication on this established imaging progression marker for the first time. Methods Fifteen PD patients underwent dMRI OFF and ON-medication one day apart. ON-medication, patients were tested approximately 45 min after their usual dose of antiparkinsonian medication. OFF-medication, patients were tested after not taking antiparkinsonian medication for > 12 h. OFF and ON-medication was counter-balanced across subjects. For dMRI, we computed free-water and free-water corrected fractional anisotropy (FAt) within the following regions: caudate, putamen, substantia nigra, and subthalamic nucleus. Results ON-medication significantly reduced parkinsonian motor symptoms compared with OFF-medication (p < 0.001). dMRI measures (free-water and FAt) were not different between the OFF and ON-medication conditions. Conclusions Administration of an acute does of anti-parkinsonian medication in PD does not affect free-water and FAt in key nigrostriatal structures. Free-water and FAt biomarkers reflect the chronic state of the nigrostriatal circuit, and therefore are potential viable biomarkers for disease-modifying therapeutic studies in PD.

Original languageEnglish (US)
Pages (from-to)417-421
Number of pages5
JournalNeuroImage: Clinical
Volume14
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Antiparkinson Agents
Diffusion Magnetic Resonance Imaging
Parkinson Disease
Anisotropy
Water
Substantia Nigra
Biomarkers
Subthalamic Nucleus
Putamen
Longitudinal Studies

Keywords

  • Antiparkinsonian medication
  • dMRI
  • Free-water
  • Free-water corrected fractional anisotropy
  • Parkinson's disease

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Neurology
  • Clinical Neurology
  • Cognitive Neuroscience

Cite this

Chung, J. W., Burciu, R. G., Ofori, E., Shukla, P., Okun, M. S., Hess, C. W., & Vaillancourt, D. E. (2017). Parkinson's disease diffusion MRI is not affected by acute antiparkinsonian medication. NeuroImage: Clinical, 14, 417-421. https://doi.org/10.1016/j.nicl.2017.02.012

Parkinson's disease diffusion MRI is not affected by acute antiparkinsonian medication. / Chung, Jae Woo; Burciu, Roxana G.; Ofori, Edward; Shukla, Priyank; Okun, Michael S.; Hess, Christopher W.; Vaillancourt, David E.

In: NeuroImage: Clinical, Vol. 14, 01.01.2017, p. 417-421.

Research output: Contribution to journalArticle

Chung, JW, Burciu, RG, Ofori, E, Shukla, P, Okun, MS, Hess, CW & Vaillancourt, DE 2017, 'Parkinson's disease diffusion MRI is not affected by acute antiparkinsonian medication', NeuroImage: Clinical, vol. 14, pp. 417-421. https://doi.org/10.1016/j.nicl.2017.02.012
Chung, Jae Woo ; Burciu, Roxana G. ; Ofori, Edward ; Shukla, Priyank ; Okun, Michael S. ; Hess, Christopher W. ; Vaillancourt, David E. / Parkinson's disease diffusion MRI is not affected by acute antiparkinsonian medication. In: NeuroImage: Clinical. 2017 ; Vol. 14. pp. 417-421.
@article{a3bc2af2a1ab493989ef82fc60b1ff5b,
title = "Parkinson's disease diffusion MRI is not affected by acute antiparkinsonian medication",
abstract = "Objective A prior longitudinal study demonstrates that free-water diffusion magnetic resonance imaging (dMRI) tracks progression in the substantia nigra (Ofori et al., 2015b). Here, we test the acute effects of antiparkinsonian medication on this established imaging progression marker for the first time. Methods Fifteen PD patients underwent dMRI OFF and ON-medication one day apart. ON-medication, patients were tested approximately 45 min after their usual dose of antiparkinsonian medication. OFF-medication, patients were tested after not taking antiparkinsonian medication for > 12 h. OFF and ON-medication was counter-balanced across subjects. For dMRI, we computed free-water and free-water corrected fractional anisotropy (FAt) within the following regions: caudate, putamen, substantia nigra, and subthalamic nucleus. Results ON-medication significantly reduced parkinsonian motor symptoms compared with OFF-medication (p < 0.001). dMRI measures (free-water and FAt) were not different between the OFF and ON-medication conditions. Conclusions Administration of an acute does of anti-parkinsonian medication in PD does not affect free-water and FAt in key nigrostriatal structures. Free-water and FAt biomarkers reflect the chronic state of the nigrostriatal circuit, and therefore are potential viable biomarkers for disease-modifying therapeutic studies in PD.",
keywords = "Antiparkinsonian medication, dMRI, Free-water, Free-water corrected fractional anisotropy, Parkinson's disease",
author = "Chung, {Jae Woo} and Burciu, {Roxana G.} and Edward Ofori and Priyank Shukla and Okun, {Michael S.} and Hess, {Christopher W.} and Vaillancourt, {David E.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.nicl.2017.02.012",
language = "English (US)",
volume = "14",
pages = "417--421",
journal = "NeuroImage: Clinical",
issn = "2213-1582",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Parkinson's disease diffusion MRI is not affected by acute antiparkinsonian medication

AU - Chung, Jae Woo

AU - Burciu, Roxana G.

AU - Ofori, Edward

AU - Shukla, Priyank

AU - Okun, Michael S.

AU - Hess, Christopher W.

AU - Vaillancourt, David E.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Objective A prior longitudinal study demonstrates that free-water diffusion magnetic resonance imaging (dMRI) tracks progression in the substantia nigra (Ofori et al., 2015b). Here, we test the acute effects of antiparkinsonian medication on this established imaging progression marker for the first time. Methods Fifteen PD patients underwent dMRI OFF and ON-medication one day apart. ON-medication, patients were tested approximately 45 min after their usual dose of antiparkinsonian medication. OFF-medication, patients were tested after not taking antiparkinsonian medication for > 12 h. OFF and ON-medication was counter-balanced across subjects. For dMRI, we computed free-water and free-water corrected fractional anisotropy (FAt) within the following regions: caudate, putamen, substantia nigra, and subthalamic nucleus. Results ON-medication significantly reduced parkinsonian motor symptoms compared with OFF-medication (p < 0.001). dMRI measures (free-water and FAt) were not different between the OFF and ON-medication conditions. Conclusions Administration of an acute does of anti-parkinsonian medication in PD does not affect free-water and FAt in key nigrostriatal structures. Free-water and FAt biomarkers reflect the chronic state of the nigrostriatal circuit, and therefore are potential viable biomarkers for disease-modifying therapeutic studies in PD.

AB - Objective A prior longitudinal study demonstrates that free-water diffusion magnetic resonance imaging (dMRI) tracks progression in the substantia nigra (Ofori et al., 2015b). Here, we test the acute effects of antiparkinsonian medication on this established imaging progression marker for the first time. Methods Fifteen PD patients underwent dMRI OFF and ON-medication one day apart. ON-medication, patients were tested approximately 45 min after their usual dose of antiparkinsonian medication. OFF-medication, patients were tested after not taking antiparkinsonian medication for > 12 h. OFF and ON-medication was counter-balanced across subjects. For dMRI, we computed free-water and free-water corrected fractional anisotropy (FAt) within the following regions: caudate, putamen, substantia nigra, and subthalamic nucleus. Results ON-medication significantly reduced parkinsonian motor symptoms compared with OFF-medication (p < 0.001). dMRI measures (free-water and FAt) were not different between the OFF and ON-medication conditions. Conclusions Administration of an acute does of anti-parkinsonian medication in PD does not affect free-water and FAt in key nigrostriatal structures. Free-water and FAt biomarkers reflect the chronic state of the nigrostriatal circuit, and therefore are potential viable biomarkers for disease-modifying therapeutic studies in PD.

KW - Antiparkinsonian medication

KW - dMRI

KW - Free-water

KW - Free-water corrected fractional anisotropy

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=85013682960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013682960&partnerID=8YFLogxK

U2 - 10.1016/j.nicl.2017.02.012

DO - 10.1016/j.nicl.2017.02.012

M3 - Article

C2 - 28275542

AN - SCOPUS:85013682960

VL - 14

SP - 417

EP - 421

JO - NeuroImage: Clinical

JF - NeuroImage: Clinical

SN - 2213-1582

ER -